Patients' and physicians' perspectives on pharmacogenetic testing

被引:95
作者
Rogausch, A
Prause, D
Schallenberg, A
Brockmöller, J
Himmel, W
机构
[1] Univ Gottingen, Dept Gen Practice Family Med, D-37073 Gottingen, Germany
[2] Univ Gottingen, Dept Clin Pharmacol, D-37073 Gottingen, Germany
关键词
attitude of health personnel; delivery of healthcare; ethics; patient acceptance of healthcare; pharmacogenetics;
D O I
10.2217/14622416.7.1.49
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The integration of pharmacogenetic testing into routine care will, in part, depend upon the patients' and physicians' acceptance of these tests. Empirical data regarding patients' and physicians' views on pharmacogenetic testing are lacking. Objectives: To explore patients' and physicians' perspectives on the potential implications of pharmacogenetic testing, particularly focusing on asthma, and to analyze the possible determinants of their expectations, hopes and fears. Methods: We conducted telephone interviews with patients with asthma or chronic obstructive pulmonary disease taking part in a larger pharmacogenetic study, in addition to general practitioners (GPs) from a different region in Germany. A total of 328 patients and 378 GPs were invited to participate. Determinants of their attitudes toward pharmacogenetic testing were assessed using logistic regression analysis. Results: Informed consent to participate in this study was given by 196 patients (60%) and 106 GPs (28%). Most patients (96%) and physicians (52%) appreciated the availability of pharmacogenetic tests for a disease such as asthma. Approximately a third of the patients worried about potential unfavorable test results (35%) and violation of privacy (36%). Female patients were more likely to have a fearful attitude (odds ratio [OR]=2.85; 95% confidence interval [CI]=1.58-5.12). Younger patients were generally more likely to be hopeful about the usefulness of pharmacogenetic testing (OR=2.12; CI=1.01-4.46). The GPs' concerns were mainly related to the possibility that patients might either be put under pressure to be tested (72%) or be disadvantaged at private health insurance agencies (61%). The nature of the responsible institution, the clarity of the research aim and explicit informed consent from patients influenced a physicians' decision regarding whether to support a pharmacogenetic study. Conclusion: The concerns of patients and GPs differ somewhat with respect to negative psychosocial consequences, discrimination or violation of privacy. Development of information for physicians and patients would be helpful in preventing unrealistic fears or hopes.
引用
收藏
页码:49 / 59
页数:11
相关论文
共 49 条
[1]   A lay prescription for tailor-made drugs -: focus group reflections on pharmacogenomics [J].
Almarsdóttir, AB ;
Björnsdóttir, I ;
Traulsen, JM .
HEALTH POLICY, 2005, 71 (02) :233-241
[2]   Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population [J].
Berth, H ;
Balck, F ;
Dinkel, A .
GENETIC TESTING, 2002, 6 (04) :273-280
[3]   Informed lay preferences for delivery of racially varied pharmacogenomics [J].
Bevan, JL ;
Lynch, JA ;
Dubriwny, TN ;
Harris, TM ;
Achter, PJ ;
Reeder, AL ;
Condit, CM .
GENETICS IN MEDICINE, 2003, 5 (05) :393-399
[4]  
Emery J, 2001, Health Expect, V4, P81, DOI 10.1046/j.1369-6513.2001.00124.x
[5]   The challenge of integrating genetic medicine into primary care [J].
Emery, J ;
Hayflick, S .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7293) :1027-1030
[6]  
EMILIEN G, 2000, Q J MED, V93, P7
[7]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[8]   Rational or rationed medicine? The promise of genetics for improved clinical practice [J].
Fears, R ;
Roberts, D ;
Poste, G .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7239) :933-935
[9]  
Freund Carol L, 2002, Am J Pharmacogenomics, V2, P273, DOI 10.2165/00129785-200202040-00007
[10]   Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? [J].
Gardiner, SJ ;
Begg, EJ .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (05) :365-369